ArticleSkeletal radiology2016
Desmoid fibromatosis: MRI features of response to systemic therapy.
Article in Skeletal radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis.Radiology. Imaging cancer · 2021Pooled it
- Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Review
- MRI assessment of tumor behavior in desmoid-type fibromatosis during active surveillance.European radiology · 2026Article
- A follow-up study on the novel use of contrast-enhanced susceptibility-weighted imaging for extremity desmoid fibromatosis response assessment.Scientific reports · 2025Article
- MRI features that predict progression of residual disease after ablation of extra-abdominal desmoid fibromatosis.European radiology · 2025Article
- Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis.Acta oncologica (Stockholm, Sweden) · 2024Article
- MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results.Frontiers in oncology · 2023Article
- Article
- Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Tenosynovial giant cell tumor-diffuse type, treated with a novel colony-stimulating factor inhibitor, pexidartinib: initial experience with MRI findings in three patients.Skeletal radiology · 2022Article
- Update of pediatric soft tissue tumors with review of conventional MRI appearance-part 1: tumor-like lesions, adipocytic tumors, fibroblastic and myofibroblastic tumors, and perivascular tumors.Skeletal radiology · 2022Review
- Differential diagnosis of T2 hypointense masses in musculoskeletal MRI.Skeletal radiology · 2021Review
- Pseudoaneurysm within a desmoid tumor in an extremity: report of 2 cases.Skeletal radiology · 2021Article
- Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.Journal of cancer research and clinical oncology · 2021Article
- Percutaneous Microwave Ablation of Desmoid Fibromatosis.Korean journal of radiology · 2021Article
- Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.British journal of cancer · 2021Review
- MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis.Frontiers in oncology · 2021Article
- The value of the black fiber sign on T1-weighted images for predicting stability of desmoid fibromatosis managed conservatively.European radiology · 2020Observational
- Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis.European radiology · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImaging criteria for measuring the response of desmoid fibromatosis to systemic therapy are not well established. We evaluated a series of patients with desmoids who underwent systemic therapy to document magnetic resonance imaging (MRI) features associated with a positive clinical response. MATERIALS AND
methodsThis Institutional Review Board-approved retrospective study included 23 patients (mean age 40.5) with 29 extra-abdominal tumors. Therapeutic regimens included cytotoxic chemotherapy (n = 19), targeted therapy (n = 3), and nonsteroid anti-inflammatory drugs (NSAIDS; n = 1). Clinical effects were categorized as progressive disease, stable, or partial response. Maximum tumor dimension (Dmax), approximate tumor volume (VTumor), and quantitative tumor T2 hyperintensity and contrast enhancement (relative to muscle) for pre- and post-treatment MRIs were compared.
resultsThree lesions progressed, 5 lesions were stable, whereas 21 showed a clinical response. Dmax decreased more in responders (mean -11.0 %) than in stable/progressive lesions (mean -3.6 and 0 % respectively, p = 0.28, ANOVA); by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) 27 out of 29 lesions were "stable," including the 3 progressive lesions. In responders, VTumor change averaged -29.4 %, but -19.2 % and +32.5 % in stable and progressive lesions respectively (p = 0.002, ANOVA); by 3D criteria 14 out of 29 lesions showed a partial response. T2 hyperintensity decreased by 50-54 % in partial response/stable disease, but only by 10 % in progressive lesions (p = 0.049, t test). Changes in contrast enhancement ranged from -23 % to 0 %, but were not statistically significant among response groups (p = 0.37). Change in T2 hyperintensity showed a positive correlation with volumetric change (r = 0.40).
conclusionDecreases in volume and T2 hyperintensity reflect the positive response of desmoid fibromatosis to systemic therapy; RECIST 1.1 criteria are not sensitive to clinically determined tumor response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.